Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05075889 · ClinicalTrials.gov registry record · Early Phase 1
Utility of ICG in Benign Bone Tumors
A Early Phase 1 study of Bone Tumor, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT05075889: Completed Early Phase 1 study of Bone Tumor, sponsored by Dartmouth-Hitchcock Medical Center.
NCT05075889 is a Early Phase 1 study of Bone Tumor that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 2 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05075889, a Early Phase 1 study of Bone Tumor, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with a biopsy-proven benign bone tumor for which standard of care is intralesional operative management will receive a weight-appropriate IV dose of indocyanine green (ICG, FDA-approved) the day prior to surgery during their standard pre-operative clinic visit. On the day of surgery, fluorescence images will be obtained using a non-invasive fluorescence camera.
Primary Outcome
fluorescence contrast suitable to facilitate fluorescence-guided surgical resection of benign bone tumors (tumor-to-background ratio \> 2.0)
Conditions Studied
Interventions
- DRUG Indocyanine Green
Study Locations (1)
New Hampshire
- Dartmouth-Hitchock - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-11-11 |
| Est. Completion | 2022-04-20 |
| Phase | Early Phase 1 |
What the finished NCT05075889 record still lists
NCT05075889 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Bone Tumor appearing as the primary indexed condition, and to 1 intervention - of which Indocyanine Green is the first listed.
NCT05075889 reports a single indexed study location in New Hampshire.
Frequently Asked Questions
What is clinical trial NCT05075889 about?
NCT05075889 is a clinical study titled "Utility of ICG in Benign Bone Tumors". Patients with a biopsy-proven benign bone tumor for which standard of care is intralesional operative management will receive a weight-appropriate IV dose of indocyanine green (ICG, FDA-approved) the day prior to surgery during their standard pre-operative clinic visit. On the day of surgery, fluore...
What is the current status of trial NCT05075889?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2021-11-11. Estimated completion is 2022-04-20.
What conditions does trial NCT05075889 study?
This clinical trial studies the following conditions: Bone Tumor.
What interventions are being tested in trial NCT05075889?
The interventions under investigation include: Indocyanine Green (DRUG).
Who is sponsoring clinical trial NCT05075889?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05075889 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bone Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05075889's enrollment target sits among peer trials
2 1974th of 2000 higher than 16 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI